Skip to main content

Table 1 Baseline demographic and clinical characteristics of patients with UC initiating tofacitinib, vedolizumab or a TNFi

From: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

Demographics Tofacitinib (N = 225) Vedolizumab (N = 373) TNFi (N = 940)
Duration of variable-length baseline period (years), mean (SD) 3.4 (1.8) 3.5 (1.8) 3.5 (1.8)
Age at index date (years), mean (SD) 45.6 (16.5) 48.7 (18.0) 45.8 (17.1)
Gender, n (%)
 Female 113 (50.2) 188 (50.4) 466 (49.6)
 Male 112 (49.8) 185 (49.6) 474 (50.4)
Biologic treatment history, n (%)
 Biologic-naïve 43 (19.1) 307 (82.3) 881 (93.7)
 1 prior biologic 92 (40.9) 49 (13.1) 49 (5.2)
 ≥ 2 prior biologics 90 (40.0) 17 (4.6) 10 (1.1)
Oral corticosteroid use, n (%)a 173 (76.9) 254 (68.1) 693 (73.7)
Geographic region, n (%)
 Northeast 26 (11.6) 46 (12.3) 102 (10.9)
 Midwest 49 (21.8) 108 (29.0) 263 (28.0)
 South 97 (43.1) 162 (43.4) 427 (45.4)
 West 53 (23.6) 57 (15.3) 148 (15.7)
12-month baseline Quan-Charlson comorbidity score, mean (SD) 0.7 (1.3) 0.8 (1.5) 0.8 (1.3)
12-month baseline Quan-Charlson comorbidity score, n (%)
 0 152 (67.6) 233 (62.5) 602 (64.0)
 1 34 (15.1) 57 (15.3) 154 (16.4)
 2 23 (10.2) 48 (12.9) 97 (10.3)
 3 8 (3.6) 13 (3.5) 45 (4.8)
 4 3 (1.3) 9 (2.4) 22 (2.3)
 ≥ 5 5 (2.2) 13 (3.5) 20 (2.1)
  1. n, number of patients in the specified category; N, number of patients in the treatment group; SD, standard deviation; TNFi, tumour necrosis factor inhibitor; UC, ulcerative colitis
  2. aDuring the 12-month baseline period